References
- Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O’Reilly DA, Cunningham D, Wadsley J, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–1024. doi:https://doi.org/10.1016/S0140-6736(16)32409-6.
- Goldstein D, Von Hoff DD, Chiorean EG, Reni M, Tabernero J, Ramanathan RK, Botteman M, Aly A, Margunato-Debay S, Lu B, et al. Nomogram for estimating overall survival in patients with metastatic pancreatic cancer. Pancreas. 2020;49(6):744–750. doi:https://doi.org/10.1097/MPA.0000000000001563.
- Azar I, Virk G, Esfandiarifard S, Wazir A, Mehdi S. Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study. J Gastrointest Oncol. 2019;10(4):703–711. doi:https://doi.org/10.21037/jgo.2018.07.08.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:https://doi.org/10.3322/caac.21590.
- Takada T, Yasuda H, Amano H, Yoshida M, Uchida T. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival? Hepatogastroenterology. 1997;44:567–573.
- Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, Schulick RD, Pawlik TM. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110(11):2484–2492. doi:https://doi.org/10.1002/cncr.23074.
- Klein F, Puhl G, Guckelberger O, Pelzer U, Pullankavumkal JR, Guel S, Neuhaus P, Bahra M. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract. 2012;2012:939350. doi:https://doi.org/10.1155/2012/939350.
- de Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, Eckhauser F, Herman JM, Edil BH, Choti MA, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102(3):256–263. doi:https://doi.org/10.1002/jso.21610.
- Singh A, Singh T, Chaudhary A. Synchronous resection of solitary liver metastases with pancreaticoduodenectomy. Jop. 2010;11:434–438.
- Tachezy M, Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M, Perinel J, Adham M, Dervenis C, Agalianos C, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160(1):136–144. doi:https://doi.org/10.1016/j.surg.2016.02.019.
- Frigerio I, Regi P, Giardino A, Scopelliti F, Girelli R, Bassi C, Gobbo S, Martini PT, Capelli P, D’Onofrio M, et al. Downstaging in stage IV pancreatic cancer: a new population eligible for surgery? Ann Surg Oncol. 2017;24(8):2397–2403. doi:https://doi.org/10.1245/s10434-017-5885-4.
- Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836–847. doi:https://doi.org/10.1245/s10434-008-0295-2.
- Riall TS, Cameron JL, Lillemoe KD, Winter JM, Campbell KA, Hruban RH, Chang D, Yeo CJ. Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery. 2006;140(5):764–772. doi:https://doi.org/10.1016/j.surg.2006.04.006.
- Yasukawa M, Kawaguchi T, Kawai N, Tojo T, Taniguchi S. Surgical treatment for pulmonary metastasis of pancreatic ductal adenocarcinoma: study of 12 cases. Anticancer Res. 2017;37:5573–5576.
- Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, Edil BH, Pawlik TM, Schulick RD, Cameron JL, et al. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg. 2011;15(9):1611–1617. doi:https://doi.org/10.1007/s11605-011-1605-8.
- Tagawa T, Ito K, Fukuzawa K, Okamoto T, Yoshimura A, Kawasaki T, Masuda T, Iwaki K, Terashi T, Okamoto M, et al. Surgical resection for pulmonary metastasis from pancreatic and biliary tract cancer. Anticancer Res. 2017;37:1413–1416.
- Pishvaian MJ, Blais EM, Brody JR, Sohal D, Hendifar AE, Chung V, Mikhail S, Rahib L, Lyons E, Tibbetts L, et al. Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: results from the Know Your Tumor (KYT) program. Journal of Clinical Oncology. 2019;37(4_suppl):191. doi:https://doi.org/10.1200/JCO.2019.37.4_suppl.191.
- Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, et al. Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms. J Natl Cancer Inst. 2018;110(10):1067–1074. doi:https://doi.org/10.1093/jnci/djy024.
- Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111(6):1132–1138. doi:https://doi.org/10.1038/bjc.2014.418.
- Reiss KA, Yu S, Judy R, Symecko H, Nathanson KL, Domchek SM. Retrospective survival analysis of patients with advanced pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations. JCO Precision Oncology. 2018;(2):1–9. doi:https://doi.org/10.1200/PO.17.00152.
- Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14(5):1291–1295. doi:https://doi.org/10.1158/1078-0432.CCR-07-2238.
- Stoffel EM, McKernin SE, Brand R, Canto M, Goggins M, Moravek C, Nagarajan A, Petersen GM, Simeone DM, Yurgelun M, et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37(2):153–164. doi:https://doi.org/10.1200/JCO.18.01489.
- Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, Chiorean EG, Chung V, Czito B, Del Chiaro M, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:439–457.
- Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O’Reilly EM. An emerging paradigm for germline testing in pancreatic ductal adenocarcinoma and immediate implications for clinical practice: a review. JAMA Oncol. 2020;6(5):764–771. doi:https://doi.org/10.1001/jamaoncol.2019.5963.
- Macherla S, Laks S, Naqash AR, Bulumulle A, Zervos E, and Muzaffar M. Emerging role of immune checkpoint blockade in pancreatic cancer. Int J Mol Sci 2018;19(11):193505.
- Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med. 2017;377(15):1409–1412. doi:https://doi.org/10.1056/NEJMp1709968.
- Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A. PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting. Prz Menopauzalny. 2016;15:215–219.
- Rimar KJ, Tran PT, Matulewicz RS, Hussain M, Meeks JJ. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. Cancer. 2017;123(11):1912–1924. doi:https://doi.org/10.1002/cncr.30631.
- Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista SC, Wiesmüller L, Seufferlein T, Kleger A. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives. Gut. 2021;70(3):606–617. doi:https://doi.org/10.1136/gutjnl-2019-319984.
- Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A. Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC Cancer. 2020;20(1):507. doi:https://doi.org/10.1186/s12885-020-06948-5.
- Golan T, O’Kane GM, Denroche RE, Raitses-Gurevich M, Grant RC, Holter S, Wang Y, Zhang A, Jang GH, Stossel C, et al. Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology. 2021;160(6):2119–2132.e9. doi:https://doi.org/10.1053/j.gastro.2021.01.220.
- Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi:https://doi.org/10.1056/NEJMoa1903387.
- Moffat GT, O’Reilly EM. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma. Clin Adv Hematol Oncol. 2020;18:168–179.
- Golan T, Varadhachary GR, Sela T, Fogelman DR, Halperin N, Shroff RT, Halparin S, Xiao L, Aderka D, Maitra A, et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. Journal of Clinical Oncology. 2018;36:297.
- Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, Karlan BY, Taniguchi T, Swisher EM. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011;29(22):3008–3015. doi:https://doi.org/10.1200/JCO.2010.34.2980.
- Ganesan S. Tumor suppressor tolerance: reversion mutations in BRCA1 and BRCA2 and resistance to PARP inhibitors and platinum. JCO Precision Oncology. 2018;(2):1–4. doi:https://doi.org/10.1200/PO.18.00001.
- Bunting SF, Callén E, Wong N, Chen H-T, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010;141(2):243–254. doi:https://doi.org/10.1016/j.cell.2010.03.012.
- Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010;17(6):1132–1138. doi:https://doi.org/10.1038/nsmb.1831.
- Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015;521(7553):541–544. doi:https://doi.org/10.1038/nature14328.
- Zimmermann M, Lottersberger F, Buonomo SB, Sfeir A, de Lange T. 53BP1 regulates DSB repair using Rif1 to control 5ʹ end resection. Science. 2013;339(6120):700–704. doi:https://doi.org/10.1126/science.1231573.
- Chapman JR, Barral P, Vannier JB, Borel V, Steger M, Tomas-Loba A, Sartori AA, Adams IR, Batista FD, Boulton SJ. RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. Mol Cell. 2013;49(5):153–164. doi:https://doi.org/10.1016/j.molcel.2013.01.002.
- D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst). 2018;71:172–176. doi:https://doi.org/10.1016/j.dnarep.2018.08.021.
- Reyngold M, O’Reilly EM, Varghese AM, Fiasconaro M, Zinovoy M, Romesser PB, Wu A, Hajj C, Cuaron JJ, Tuli R, et al. Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer. JAMA Oncol. 2021;7(5):735. doi:https://doi.org/10.1001/jamaoncol.2021.0057.